On the Precipice of a "Rituximab-Like" Era for T-Cell Lymphomas?
- PMID: 37581573
- DOI: 10.1158/1078-0432.CCR-23-1571
On the Precipice of a "Rituximab-Like" Era for T-Cell Lymphomas?
Abstract
To date, mAbs have had limited success in improving outcomes for patients with T-cell lymphomas. Preclinical data suggest that anti-T-cell receptor Vβ-segment mAbs are a novel therapeutic strategy for patients with T-cell lymphomas that avoid several limitations of current therapies. See related article by Lucero et al., p. 4230.
©2023 American Association for Cancer Research.
Comment on
-
Patient-Specific Targeting of the T-Cell Receptor Variable Region as a Therapeutic Strategy in Clonal T-Cell Diseases.Clin Cancer Res. 2023 Oct 13;29(20):4230-4241. doi: 10.1158/1078-0432.CCR-22-0906. Clin Cancer Res. 2023. PMID: 37199721 Free PMC article.
Publication types
LinkOut - more resources
Full Text Sources
